Renuvion® dermal handpiece for wrinkle-reduction procedures cleared by fda

Revolutionary apyx medical device used by top physicians in the us now available to patients for nonsurgical facial renewal  clearwater, fla. , june 28, 2022 /prnewswire/ -- apyx medical corporation (nasdaq: apyx), the manufacturer of renuvion®, a proprietary helium plasma and radiofrequency technology, previously announced the receipt of 510(k) clearance from the u.s. food and drug administration ("fda") for the use of the renuvion dermal handpiece for specific dermatological procedures for the treatment of moderate to severe wrinkles and rhytides, limited to patients with fitzpatrick skin types i, ii or iii.
APYX Ratings Summary
APYX Quant Ranking